Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1431.617
- +9.442+0.66%
Beam Therapeutics Picks Ironwood Pharmaceuticals Finance and Operations Chief as CFO
Thursday Indexes Pull back From Records While Bitcoin Sets New Ones | Wall Street Today
12 Health Care Stocks Moving In Thursday's Pre-Market Session
100k Bitcoin! Market Pulls Back After Records | Live Stock
FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program
Bluebird Bio Shares Are Trading Higher After the Company Announced It Joined the CMMI Cell and Gene Therapy Access Model and Will Offer Outcomes-based Agreements to Expand Medicaid Access to LYFGENIA Gene Therapy for Sickle Cell Disease.
CMS Rolls Out New Payment Model for Vertex, Bluebird Gene Therapies
10 Health Care Stocks Whale Activity In Today's Session
S&P and Nasdaq on Track for Third Record Close This Week | Live Stock
Ready Capital Corporation Announces Pricing of Public Offering of Senior Notes Due 2029
Fresh Closing Highs from S&P 500 and Nasdaq | Wall Street Today
Tuesday S&P 500 Pulls Back From Highs, Nasdaq Climbs | Live Stock
S&P 500 and Nasdaq Hit Closing and Trading Highs Monday | Wall Street Today
December Starts With a Mixed Market | Live Stock
NeuroSense Therapeutics Shares Climbed on $5M Private Placement
Cathie Wood Sees Tesla As 'Largest AI Project On Earth' — Here's Why She's Not Worried About Tech Investments
Wednesday Ends With Index Decline | Wall Street Today
FDA Investigating Safety Risks of Bluebird's Skysona
FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock